Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
April 9, 2019 Off

Peloton Therapeutics Announces Completion of Enrollment in Phase 2 Trial of PT2977 for Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma

By BusinessWire

– Topline results anticipated in first half of 2020 – DALLAS–(BUSINESS WIRE)–Peloton Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing first-in-class…

April 9, 2019 Off

Azitra Receives Ongoing Support for Its Netherton Development Program from the National Science Foundation (NSF)

By BusinessWire

— Phase II Grant to Advance Development of Live Biotherapeutic Product Candidate for Netherton Syndrome — FARMINGTON, Conn.–(BUSINESS WIRE)–Azitra, Inc.…

April 9, 2019 Off

The Government of Armenia Signs Strategic Partnership with WHISE-Embleema to Modernize Digital Healthcare Through Blockchain

By BusinessWire

The Republic of Armenia Ministry of Health embraces national digital health agenda, partnering with WHISE-Embleema to digitize healthcare data in…

April 9, 2019 Off

Revance Appoints Former Allergan Marketing Veteran Taryn Conway as Vice President of Marketing

By BusinessWire

NEWARK, Calif.–(BUSINESS WIRE)–Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic…

April 9, 2019 Off

Lyndra Therapeutics Takes on Opioid Use Disorder with Long-Acting Oral Dosage Form

By BusinessWire

NIH Grant Fuels Development of Once-Weekly Oral Buprenorphine WATERTOWN, Mass.–(BUSINESS WIRE)–Lyndra Therapeutics, the company making daily pills a thing of…

April 9, 2019 Off

Frequency Therapeutics Announces Positive Phase 1/2 Data for Drug Candidate for Hearing Restoration

By BusinessWire

Primary safety endpoint met as FX-322 was well tolerated Preliminary clinical data suggests improvement on measures of hearing function Company…

April 9, 2019 Off

Ra Pharmaceuticals Announces Completion of End-of-Phase 2 Interactions with FDA and Design of Pivotal Phase 3 gMG Study

By BusinessWire

Alignment with FDA on a single, pivotal, 12-week, placebo-controlled, Phase 3 clinical trial to initiate in the second half of…

April 9, 2019 Off

NanOlogy announces First Patient Enrolled in a Phase 1/2 Clinical Trial of NanoDoce® for Treatment of Bladder Cancer

By BusinessWire

NanOlogy may offer an alternative treatment option for patients with bladder cancer Investigational drug, NanoDoce, is injected locally into tumor…

April 9, 2019 Off

MaaT Pharma Announces Second Positive DSMB Safety Assessment of Phase II HERACLES Study in Acute GvHD

By BusinessWire

—Independent Data Safety Monitoring Board (DSMB) recommends HERACLES trial to continue without modification— —Patient recruitment in the study continues with…

April 9, 2019 Off

Arcadia Biosciences Welcomes Dr. Randy Shultz as Head of Research and Development

By BusinessWire

— Experienced R&D strategist brings deep expertise in advanced breeding and gene editing technologies — DAVIS, Calif.–(BUSINESS WIRE)–Arcadia Biosciences, Inc.…

Posts pagination

Previous 1 … 3,289 3,290 3,291 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine